Neutrophils are major effectors and regulators of the immune system. They play critical roles
not only in the eradication of pathogens but also in cancer initiation and progression …

Since the past decades, more lung cancer patients have been experiencing lasting benefits
from immunotherapy. It is imperative to accurately and intelligently select appropriate …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in
cancer patients, but clinical responses are limited. Cytokine signaling through the Janus …

Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis,
calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental …

Progress in sequencing technologies and clinical experiments has revolutionized
immunotherapy on solid and hematologic malignancies. However, the benefits of …

Purpose: We sought to identify features of patients with advanced non–small cell lung
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors …

Neoadjuvant immunotherapy has significantly changed the therapeutic approach for treating
patients with surgically resectable non‐small cell lung cancer (NSCLC). Here, peripheral …

Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell
lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity …

In the era of immunotherapy, identifying biomarkers of immune system activation has
become a high-priority challenge. The blood neutrophil-to-lymphocyte ratio (NLR) has been …